Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 505 - 512 of 12089 results

Employers See Spike in Pregnant Worker Lawsuits
December 1, 2024| News

The Business of Biotech
November 29, 2024| News

The Life Sci Fantastic Podcast - The Business of Biotech
November 28, 2024| Podcast| Viewpoint

Department of Homeland Security Designates Lebanon for TPS and Provides for DED-EAD Application
November 27, 2024| Alert| Viewpoint

Telephone and Texting Compliance News — November 2024
November 27, 2024| Article| Viewpoint

Telephone and Texting Compliance News: Regulatory Update — Federal Communications Commission Allows Third-Party Call Authentication
November 27, 2024| Article| Viewpoint

Telephone and Texting Compliance News: Litigation Update — A Win for TCPA Compliance and the Lead Generation Industry
November 27, 2024| Article| Viewpoint

GOP Election Sweep Threatens Niche College Tax Break
November 27, 2024| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
